{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Rash"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Safety summaries will include tabulations in the form of tables and listings. The number of participants affected by treatment-emergent adverse events will be reported.","groups":[{"description":"Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nErlotinib Hydrochloride: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Erlotinib Hydrochloride)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days","title":"Incidence of Clinically Significant, Non-hematologic Grade 3 or 4 Toxicities at Least Possibly Related to Erlotinib Hydrochloride","type":"PRIMARY","unitOfMeasure":"Participants"}